Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, for the treatment of advanced malignant solid tumors. JSKN027 is the company's fifth ADC candidate entering clinical development, as well as the world's first PD-L1/ VEGFR2 bispecific ADC to advance into clinical trials.

As the global burden of malignant tumors continues to rise, there is an urgent clinical need for more effective and innovative therapies applicable across various tumor types. PD-L1 is a key molecule in regulating immune responses, and VEGFR2 is a core signaling hub in tumor angiogenesis. Within the immunosuppressive microenvironment of various solid tumors, the VEGF/VEGFR signaling pathway and the PD-1/PD-L1 axis exhibit a synergistic interplay, collectively driving immune evasion and providing a new strategy for dual-target therapy. JSKN027 is an innovative bispecific ADC designed based on this synergistic mechanism. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody's Fc region. This design confers multiple mechanisms of action, including targeted chemotherapy, anti-angiogenesis and immunotherapy. It is expected to synergistically enhance antitumor efficacy and overcome therapeutic resistance, offering a promising treatment strategy across solid tumors.

JSKN027-101 is an open-label, multi-center, Phase I clinical study, including dose-escalation and dose-expansion phases. This study aims to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and antitumor activity of JSKN027 in patients with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).